Added to YB: 2026-03-06
Pitch date: 2026-03-04
CYTK [bullish]
Cytokinetics, Incorporated
Author Info
No bio for this author
Company Info
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Market Cap
$7.5B
Pitch Price
N/A
Price Target
90.00
Dividend
N/A
EV/EBITDA
-13.34
P/E
-9.29
EV/Sales
91.27
Sector
Biotechnology
Category
growth
Cytokinetics CYTK Part 1: A Commercial Biotech in the Making
CYTK: Myqorzo (aficamten) approved Dec '26 for oHCM w/ broader label vs BMY's Camzyos ($1.3B 2026 sales). MAPLE beat metoprolol h2h: +2.3 mL/kg/min peak VO2, −30 mmHg LVOT gradient, 51% vs 26% NYHA improvement. Simpler dosing: 3 vs 4 mandatory echos, LVEF threshold 40% vs 50%, fewer DDIs. Mgmt targets >50% CMI-naive share by YE. Peak sales est ~$5B w/ ACACIA-nHCM readout Q2 (±30% catalyst). PT $90, +45% upside.
Read full article (5 min)